Today, February 23rd, 2026, Gilead Sciences announced a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion, providing Gilead with full ownership of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR-T therapy for patients with relapsed or refractory multiple myeloma. Arcellx is a clinical-stage biotech company headquartered in Rockville, Maryland, founded in 2014. [Read more…]
What is the difference between totipotent, pluripotent, and multipotent?
When learning about stem cells, a common question is, what is the difference between totipotent, pluripotent, and multipotent cells? The answer is simple.
The key differences between these cells are:
- When each appears during the process of human development.
- Their degree of “flexibility” to become other cell types. [Read more…]
The Future of Stem Cell Therapy as Treatment for Autism
Treatment for autism is an increasingly important pursuit, as the Center for Disease Control and Prevention (CDC) estimates:
- 1 in 59 children has been identified with autism spectrum disorder (ASD) [Read article]
- Autism occurs in all racial, ethnic, and socioeconomic groups. [Read article]
- Studies in Asia, Europe, and North America have identified ASD to have a prevalence rate of between 1% and 2%. [Data table]
With autism spectrum disorder (ASD) affecting between 1-2% of the population, the condition is becoming of increasing importance and a treatment for autism is becoming a highly sought-after medical breakthrough.
Longevity Medical Institute® Opens Federally Licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory in Los Cabos
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 3, 2026 — Longevity Medical Institute® today announced the opening of its federally licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory, further expanding what is now one of the most comprehensive regenerative and advanced diagnostic medical campuses in Los Cabos. [Read more…]
Leading Competitors within the Induced Pluripotent Stem Cell (iPSC) Market
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 337
- Next Page »